PROVECTUS BIOPHARMACEUTICALS, INC. 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Dec 10, 2015
Insider Transaction Report
Form 4
CULPEPPER PETER R
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2015-12-09$0.94/sh+138,831$130,501→ 1,251,163 total - Exercise/Conversion
Common Stock
2015-12-09$0.94/sh+6,383$6,000→ 190,503 total(indirect: By 401(k)) - Exercise/Conversion
Stock Option (right to buy)
2015-12-09−145,214→ 0 totalExercise: $0.94From: 2006-12-09Exp: 2015-12-09→ Common Stock (145,214 underlying) - Award
Stock Option (right to buy)
2015-12-09+400,000→ 400,000 totalExercise: $0.75From: 2015-12-09Exp: 2025-12-09→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]The option, representing a right to purchase a total of 175,000 shares, became exercisable in three equal installments beginning on December 9, 2006, which was the first anniversary of the date on which the option was granted.